1363381-12-7

Basic information

• Product Name: cis-tert-Butyl 3-hydroxy-3-MethylcyclobutylcarbaMate
• Synonyms: cis-tert-Butyl 3-hydroxy-3-MethylcyclobutylcarbaMate;cis-tert-Butyl 3-hydroxy-3-methylcyclobutylcarbamate - H11346
• CAS NO: 1363381-12-7
• Molecular Formula: C10H19NO3
• Molecular Weight: 201.26276
• Mol File: 1363381-12-7.mol

Chemical Properties

• Boiling Point: 304.9±31.0 °C(Predicted)
• Appearance: /
• Density: 1.08±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 12.21±0.40(Predicted)
• CAS DataBase Reference: cis-tert-Butyl 3-hydroxy-3-MethylcyclobutylcarbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: cis-tert-Butyl 3-hydroxy-3-MethylcyclobutylcarbaMate(1363381-12-7)
• EPA Substance Registry System: cis-tert-Butyl 3-hydroxy-3-MethylcyclobutylcarbaMate(1363381-12-7)

Safety Data

• Hazardous Substances Data: 1363381-12-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
cis-tert-Butyl 3-hydroxy-3-MethylcyclobutylcarbaMate is used as a pharmaceutical intermediate for its role in the synthesis of various organic compounds, contributing to the development of new drugs and agrochemicals. Its unique molecular structure and properties make it a valuable asset in the creation of innovative pharmaceutical products.
Used in Chemical Research:
In the field of chemical research, cis-tert-Butyl 3-hydroxy-3-MethylcyclobutylcarbaMate is utilized as a subject of study to explore its properties and potential applications. Its molecular structure offers opportunities for further exploration and understanding of chemical reactions and interactions, potentially leading to advancements in the chemical sciences.
Used in Drug Development:
cis-tert-Butyl 3-hydroxy-3-MethylcyclobutylcarbaMate is employed in drug development as a key component in the synthesis of new pharmaceuticals. Its potential use in creating novel drugs highlights its importance in the ongoing pursuit of medical advancements and treatments for various conditions.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1523571-03-0 (1s,3r)-3-amino-1-methylcyclobutanol hydrochloride 
• 1523571-03-0 trans-3-amino-1-methylcyclobutan-1-ol hydrochloride 
• 15760-35-7 3-methylenecyclobutanecarbonitrile 
• 15760-36-8 3-methylenecyclobutane-1-carboxylic acid 
• 1154759-69-9 (1-oxa-spiro[2.3]hex-5-yl)-carbamic acid tert-butyl ester 
• 130369-04-9 (3-methylene-cyclobutyl)-carbamic acid tert-butyl ester 
• 154748-49-9 3-(tert-butyloxycarbonylamino)cyclobutan-1-one 
• 917-54-4 methyllithium 

Relevant articles and documents

MCL-1 INHIBITORS

The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS

A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

CHEMICAL COMPOUNDS AS H-PGDS INHIBITORS

A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS FOR USE IN THE TREATMENT OF CANCER

The present inventions relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein ring A, R1, R2a, R2b, R3, R4, R4a, R5- R23, g, j, m, n, x, y, and z are defined herein. The novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

PYRROLOPYRIMIDINE AND PURINE DERIVATIVES

The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, T, V, W, X, Y, Z, ring A, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.